2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb May 7, 2025 04:05PM
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results Mar 25, 2025 04:05PM
2seventy bio (TSVT) Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb Mar 10, 2025 10:17PM
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb Mar 10, 2025 10:17PM
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference Feb 25, 2025 07:00AM
View Older Stories

Feb 6, 2025 07:04AM 2seventy bio (TSVT) Reports Preliminary Full-Year U.S. Abecma Sales
Feb 6, 2025 07:03AM 2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
Nov 12, 2024 07:00AM 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Nov 4, 2024 04:01PM 2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
Sep 25, 2024 06:13AM 2seventy bio (TSVT) Provides Update on KarMMa-9 Study, Previews Anticipated Strong Q3 Revenue
Sep 25, 2024 06:00AM 2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
Aug 29, 2024 07:00AM 2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
Aug 7, 2024 07:00AM 2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
Aug 5, 2024 07:00AM 2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
Jun 26, 2024 04:11PM 2seventy bio (TSVT) Completes $40M Deal to Sell Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk (NVO)
Jun 26, 2024 04:11PM 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
May 23, 2024 07:00AM 2seventy bio to Participate in Upcoming Investor Conferences
May 8, 2024 07:00AM 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 3, 2024 07:00AM 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
Apr 5, 2024 09:06AM U.S. FDA Approves Bristol Myers Squibb (BMY) and 2seventy bio’s (TSVT) Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Apr 5, 2024 09:05AM U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Apr 1, 2024 07:31AM 2seventy bio (TSVT) Completes Oncology and Autoimmune Pipeline Divestiture to Regeneron
Apr 1, 2024 07:30AM 2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
Mar 20, 2024 05:04PM 2seventy bio (TSVT) Appoints Eli Casdin and Charles Newton to its Board
Mar 20, 2024 05:04PM 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
Mar 15, 2024 06:27PM FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Mar 5, 2024 07:00AM 2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
Mar 1, 2024 07:00AM 2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
Feb 5, 2024 04:05PM 2seventy bio to Participate in Upcoming Investor Conferences
Feb 5, 2024 07:02AM Bristol-Myers (BMY), 2seventy bio (TSVT) announce FDA will convene meeting of ODAC on March 15 to review data supporting sBLA for Abecma
Feb 5, 2024 06:59AM Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
Jan 30, 2024 07:02AM 2seventy bio (TSVT) Announces Cost Cuts, Will Focus on Abecma
Jan 30, 2024 07:01AM 2seventy bio Announces New Strategic Path Forward
Dec 12, 2023 03:22AM Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) Report Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple
Dec 11, 2023 07:30PM Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Dec 11, 2023 07:17AM 2seventy bio (TSVT) to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma
Dec 11, 2023 07:00AM 2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
Dec 6, 2023 02:02PM 2seventy bio (TSVT) Reiterates Commitment to Maximizing Shareholder Value
Dec 6, 2023 02:00PM 2seventy bio Reiterates Commitment to Maximizing Shareholder Value
Nov 20, 2023 07:00AM Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) Provide Update on U.S. FDA Review of sBLA for Abecma
Nov 20, 2023 06:59AM Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple
Nov 14, 2023 07:00AM 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Sep 15, 2023 07:00AM Deep Genomics Announces the Appointment of Brian O’Callaghan as CEO
Sep 12, 2023 07:02AM 2seventy bio (TSVT) Announces Strategic Restructuring, CEO to Step Down
Sep 12, 2023 07:00AM 2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
Sep 12, 2023 06:55AM 2seventy bio (TSVT) and JW Therapeutics To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
Sep 12, 2023 06:55AM 2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
Sep 6, 2023 07:00AM 2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
Aug 14, 2023 07:00AM 2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
Aug 8, 2023 07:00AM 2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023
Aug 1, 2023 04:15PM 2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference  
Jun 14, 2023 07:02AM 2seventy bio (TSVT) Announces Clinical Study Pause of PLAT-08 Trial
Jun 14, 2023 07:00AM 2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
Jun 7, 2023 07:00AM 2seventy bio to Participate in Upcoming Investor Conference
May 19, 2023 06:01AM 2seventy bio (TSVT) Presents Late-Breaking Results for SC-DARIC33
View Older Stories